MedKoo Cat#: 525823 | Name: PD 117302

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PD 117302 a new nonpeptide opioid compound shown in in vitro studies to be a selective kappa-opioid agonist, has been evaluated in vivo for antinociceptive activity and other effects characteristic of kappa-receptor activation. PD 117302 also causes naloxone-reversible locomotor impairment and diuresis, effects that are typical of kappa-agonists. It is an Anti-Arrhythmia Agent, an Anticonvulsants, a Cardiovascular Agent, and a Central Nervous System Agent.

Chemical Structure

PD 117302
PD 117302
CAS#111728-01-9

Theoretical Analysis

MedKoo Cat#: 525823

Name: PD 117302

CAS#: 111728-01-9

Chemical Formula: C21H28N2OS

Exact Mass: 356.1922

Molecular Weight: 356.52

Elemental Analysis: C, 70.75; H, 7.92; N, 7.86; O, 4.49; S, 8.99

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
PD117302; PD-117302; PD 117302
IUPAC/Chemical Name
2-(benzo[b]thiophen-4-yl)-N-methyl-N-((1R,2R)-2-(pyrrolidin-1-yl)cyclohexyl)acetamide
InChi Key
SYHJZCCNQDFHJQ-RTBURBONSA-N
InChi Code
InChI=1S/C21H28N2OS/c1-22(18-8-2-3-9-19(18)23-12-4-5-13-23)21(24)15-16-7-6-10-20-17(16)11-14-25-20/h6-7,10-11,14,18-19H,2-5,8-9,12-13,15H2,1H3/t18-,19-/m1/s1
SMILES Code
O=C(N(C)[C@H]1[C@H](N2CCCC2)CCCC1)CC3=C(C=CS4)C4=CC=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 356.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Leighton GE, Hill RG, Hughes J. The effects of the kappa agonist PD-117302 on feeding behaviour in obese and lean Zucker rats. Pharmacol Biochem Behav. 1988 Oct;31(2):425-9. PubMed PMID: 2854265. 2: Leighton GE, Johnson MA, Meecham KG, Hill RG, Hughes J. Pharmacological profile of PD 117302, a selective kappa-opioid agonist. Br J Pharmacol. 1987 Dec;92(4):915-22. PubMed PMID: 2827830; PubMed Central PMCID: PMC1853714. 3: Colombo M, Petrillo P, La Regina A, Bianchi G, Tavani A. In vitro binding profile and in vivo pharmacological properties of the K-opioid compound PD 117302. Res Commun Chem Pathol Pharmacol. 1991 Jun;72(3):295-306. PubMed PMID: 1658887. 4: Porreca F, Ianone M, Wheeler H, Cowan A. Comparison of PD 117302, a kappa agonist, and morphine on colonic transit and formalin-induced pain in rats. Proc West Pharmacol Soc. 1989;32:185-7. PubMed PMID: 2550944. 5: Pugsley MK, Saint DA, Hayes ES, Abraham S, Walker MJ. An examination of the cardiac actions of PD117,302, a κ-opioid receptor agonist. Eur J Pharmacol. 2015 Aug 15;761:330-40. doi: 10.1016/j.ejphar.2015.06.018. Epub 2015 Jun 15. PubMed PMID: 26086860. 6: Moussaoui SM, Montier F, Carruette A, Blanchard JC, Laduron PM, Garret C. A non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically. Br J Pharmacol. 1993 May;109(1):259-64. PubMed PMID: 7684305; PubMed Central PMCID: PMC2175579. 7: Parrott RF, Ebenezer IS, Baldwin BA, Forsling ML. Hormonal effects of apomorphine and cholecystokinin in pigs: modification of the response to cholecystokinin by a dopamine antagonist (metoclopramide) and a kappa opioid agonist (PD117302). Acta Endocrinol (Copenh). 1991 Oct;125(4):420-6. PubMed PMID: 1957561. 8: Shukla VK, Turndorf H, Bansinath M. Pertussis and cholera toxins modulate kappa-opioid receptor agonists-induced hypothermia and gut inhibition. Eur J Pharmacol. 1995 Mar 16;292(3-4):293-9. PubMed PMID: 7796869. 9: Wheeler-Aceto H, Cowan A. Standardization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacology (Berl). 1991;104(1):35-44. PubMed PMID: 1882002. 10: Leighton GE, Hill RG, Hughes J. Effects of 5-HT and alpha 1 adrenoceptor antagonists on kappa opioid-induced sedation. Pharmacol Biochem Behav. 1988 Dec;31(4):899-904. PubMed PMID: 2855271. 11: Bansinath M, Ramabadran K, Turndorf H, Shukla VK. Intracerebroventricular administration of kappa-agonists induces convulsions in mice. Brain Res Bull. 1991 Jul;27(1):75-9. PubMed PMID: 1657321. 12: Nemmani KV, Gullapalli S, Ramarao P. Potentiation of kappa-opioid receptor agonist-induced analgesia and hypothermia by fluoxetine. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):189-93. PubMed PMID: 11420085. 13: Petrillo P, Kowalski J, Sbacchi M, Tavani A. Characterization of opioid binding sites in rat spinal cord. J Recept Res. 1992;12(1):39-57. PubMed PMID: 1314311. 14: Agbas A, Simon J, Avni Oktem H, Varga E, Borsodi A. Characterization of human placental opioid receptors by 3H-ethylketocyclazocine and 3H-naloxone binding. Neuropeptides. 1988 Oct;12(3):171-6. PubMed PMID: 2907370. 15: Carey GJ, Bergman J. Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists. J Pharmacol Exp Ther. 2001 Apr;297(1):215-23. PubMed PMID: 11259547. 16: Wilson JL, Walker JS, Antoon JS, Perry MA. Intercellular adhesion molecule-1 expression in adjuvant arthritis in rats: inhibition by kappa-opioid agonist but not by NSAID. J Rheumatol. 1998 Mar;25(3):499-505. PubMed PMID: 9517771. 17: Bansinath M, Ramabadran K, Turndorf H, Puig MM. Kappa-opiate agonist-induced inhibition of gastrointestinal transit in different strains of mice. Pharmacology. 1991;42(2):97-102. PubMed PMID: 1648236. 18: Gué M, Alvinerie M, Junien JL, Buéno L. Stimulation of kappa opiate receptors in intestinal wall affects stress-induced increase of plasma cortisol in dogs. Brain Res. 1989 Nov 13;502(1):143-8. PubMed PMID: 2555024. 19: Ribeiro W, Ifa DR, Corso G, Salmon J, Moraes LA, Eberlin MN, de Nucci G. Determination of RSD921 in human plasma by high-performance liquid chromatography-tandem mass spectrometry using tri-deuterated RSD921 as internal standard: application to a phase I clinical trial. J Mass Spectrom. 2001 Oct;36(10):1133-9. PubMed PMID: 11747107. 20: Sheridan RD. Quantification of state-dependent drug interactions with the sodium channel. Br J Pharmacol. 2000 Jan;129(2):409-11. PubMed PMID: 10694250; PubMed Central PMCID: PMC1571825.